| 发明名称 | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction | ||
| 摘要 | The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist. | ||
| 申请公布号 | US9211334(B2) | 申请公布日期 | 2015.12.15 |
| 申请号 | US201314049005 | 申请日期 | 2013.10.08 |
| 申请人 | EB IP LYBRIDOS B.V. | 发明人 | Tuiten Jan Johan Adriaan;Bloemers Johannes Martinus Maria;De Lange Robertus Petrus Johannes |
| 分类号 | A61K31/56;A61K45/06;A61K31/496;A61K31/519;A61K31/568 | 主分类号 | A61K31/56 |
| 代理机构 | Morrison & Foerster LLP | 代理人 | Morrison & Foerster LLP |
| 主权项 | 1. A pharmaceutical composition designed for acute administration in anticipation of sexual activity comprising testosterone and a 5-HT1A agonist, wherein said testosterone is formulated for sublingual, buccal-mucosal, or intranasal administration with a cyclodextrin to release the testosterone within 120 seconds after administration with peak levels of testosterone reached after about 1-20 minutes and the 5-HT1A agonist is formulated for delayed release such that 5-HT1A is released 2.5 to 4.5 hours after the release of testosterone. | ||
| 地址 | Almere NL | ||